Genbody

GenBody Inc. is a South Korean in vitro diagnostics company founded in 2012 that develops and manufactures rapid diagnostic tests (RDTs) and reagents for point-of-care applications. The company's product portfolio covers infectious diseases including COVID-19, influenza, arboviral diseases (Zika, Dengue, Chikungunya), and other conditions, with tests distributed globally across the US, Japan, Indonesia, Brazil, and Australia. GenBody holds FDA EUA and 510(k) clearances for its COVID-19 antigen tests and developed the world's first Zika and MERS-CoV rapid diagnostic tests for humans. The company is headquartered in Cheonan, South Korea, with a US affiliate, GenBody America.